Effects of Oral Tranexamic Acid Following Total Knee Arthroplasty
NCT06479161
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The primary purpose of this study is to evaluate postoperative pain. Secondary outcomes evaluated in this study will include range of motion (ROM), opioid consumption, and ambulation. Each outcome measure will be evaluated, oral tranexamic acid (TXA) in the experiment arm and placebo in the control arm, after total knee arthroplasty (TKA) at postoperative days 0-3, and weeks 1, 2, 6, and 12.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Postoperative Pain
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 89 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Matthew Grosso, MD
- Last updated on ClinicalTrials.gov
- December 13, 2024
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Trinity Health Of New England/CT Joint Replacement Institute · Hartford, CT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.